Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: John Pitera who wrote (208)	12/20/1999 9:30:00 PM
From: Jorj X Mckie	Respond to of 2850

Nice breakout on AFFX today.

To: John Pitera who wrote (208)	12/20/1999 10:57:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 2850

Have to admit, it is hard not to get enthusiastic when The Motley Fool get's this sort of write up for their CRA--I wonder if the commissioned the post? boards.fool.com There is no doubt that Celera leads in raw sequencing power. They do not lead in finding the Snips however...no mention of the SNP consortium, see www.snps.com for the details on that, but the consortium includes... The Wellcome Trust AstraZeneca PLC Bayer AG Bristol-Myers Squibb Hoffmann-La Roche Glaxo Wellcome PLC Hoechst Marion Roussel Novartis Pfizer Searle SmithKline Beecham PLC. Whitehead Institute for Biomedical Research Washington University School of Medicine in St. Louis The Wellcome Trust's Sanger Centre Stanford Human Genome Center Cold Spring Harbor Laboratory